"J Mark Access Health Policy"[Journal] - Search Results

Year	Number of Results
2013	6
2014	16
2015	24
2016	18
2017	35
2018	14
2019	31
2020	26
2021	20
2022	17
2023	30
2024	31
2025	64
2026	11

1

Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.

EI-Kersh K, Zawadzki N, Coyle C, Zhang S, Dalal D, Watzker A, Lautsch D, Shafrin J. EI-Kersh K, et al. J Mark Access Health Policy. 2026 Feb 6;14(1):9. doi: 10.3390/jmahp14010009. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41726121 Free PMC article.

2

Adopting a Societal Perspective in Health-Economic Evaluation: Analysis of Nine HTA Methodological Guidelines on How to Integrate Societal Costs.

Gervès-Pinquié C, Nanoux H, Akarkoub S, Brazeilles R, Bonnabau H, Le Lay K. Gervès-Pinquié C, et al. J Mark Access Health Policy. 2026 Feb 10;14(1):10. doi: 10.3390/jmahp14010010. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41726120 Free PMC article.

3

Evaluating [¹⁸F]-DCFPyL for Detecting Prostate Cancer Recurrence: A Cost-Consequence Comparison with Alternative PET Radiotracers in Spain.

Matos T, Godbole M, Badinedi R, Muthukumar M, Hodolic M, Tchouen N, Berthon A. Matos T, et al. J Mark Access Health Policy. 2026 Jan 23;14(1):7. doi: 10.3390/jmahp14010007. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41726119 Free PMC article.

4

A Cost-Effectiveness Analysis of the Sentio Bone Conduction Hearing Implant System in the Australian Healthcare Setting.

Värendh M, Haggren I, Lagerkvist H, Åberg Håkansson M, Hjelmgren J. Värendh M, et al. J Mark Access Health Policy. 2026 Jan 27;14(1):8. doi: 10.3390/jmahp14010008. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41726118 Free PMC article.

5

Optimising Investment in Health Innovations in Europe.

Adeyemo T, Wilsdon T, Vandorou C, Davies F, Godet A. Adeyemo T, et al. J Mark Access Health Policy. 2026 Feb 13;14(1):11. doi: 10.3390/jmahp14010011. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41726117 Free PMC article.

6

Enhancing Patient-Centered Health Technology Assessment: A Modified Delphi Panel for PICOS Scoping in Spinal Muscular Atrophy.

Arcà E, Barlassina A, Eze A, Strammiello V. Arcà E, et al. J Mark Access Health Policy. 2026 Jan 19;14(1):6. doi: 10.3390/jmahp14010006. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41726116 Free PMC article.

7

Knowledge Spillover and Innovation in Healthcare: A Comparative Study of Social Media Interaction Between Medical Technology Companies and Healthcare Professionals in Austria.

Zilahi-Lugbauer M, Stummer H. Zilahi-Lugbauer M, et al. J Mark Access Health Policy. 2025 Dec 22;14(1):1. doi: 10.3390/jmahp14010001. eCollection 2026 Mar. J Mark Access Health Policy. 2025. PMID: 41573700 Free PMC article.

8

Overcoming Patient Access Barriers in Complex Conditions: Lessons from Schizophrenia for Broader Healthcare Applications.

Burgmans S, Rieper Hald A, Markandaier ST, Hall N, Loiseau R, Lie X, Kappelhoff B. Burgmans S, et al. J Mark Access Health Policy. 2025 Dec 23;14(1):2. doi: 10.3390/jmahp14010002. eCollection 2026 Mar. J Mark Access Health Policy. 2025. PMID: 41573699 Free PMC article.

9

European Joint Clinical Assessment PICO Scoping Process: Analysis of Current Approaches and Recommendations.

D'Oca K, Darquennes E, Garrigues C, Draganigos A, Steck N. D'Oca K, et al. J Mark Access Health Policy. 2025 Dec 29;14(1):3. doi: 10.3390/jmahp14010003. eCollection 2026 Mar. J Mark Access Health Policy. 2025. PMID: 41573698 Free PMC article.

10

Conformity Assessment of Medical Devices: An Overview from a Notified Body.

Stange AF, Julian E. Stange AF, et al. J Mark Access Health Policy. 2026 Jan 8;14(1):4. doi: 10.3390/jmahp14010004. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41573697 Free PMC article.

11

Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy.

Julian E, Xander NSH, Boumaki K, Garcia MJ, Jahimovica E, Mosset-Keane J, Otto MH, Pavlovic M, Scroccaro G, Strammiello V, Bernardini R, Capri S, Casado-Arroyo R, Desmet T, Van Dyck W, Fricke FU, Gianfrate F, Solà-Morales O, Wasem J, Wörmann BJ, Ruof J. Julian E, et al. J Mark Access Health Policy. 2026 Jan 15;14(1):5. doi: 10.3390/jmahp14010005. eCollection 2026 Mar. J Mark Access Health Policy. 2026. PMID: 41573696 Free PMC article.

12

How Patients Can Contribute to the Assessments of Health Technologies.

Houÿez F, Delaye J. Houÿez F, et al. J Mark Access Health Policy. 2025 Dec 15;13(4):61. doi: 10.3390/jmahp13040061. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41450903 Free PMC article.

13

The Pharmaceutical Innovativeness Index: Supporting Value-Based Economic Regulation of Innovative Medicines.

Gargano LP, Borin MC, Prata WM, Alvares-Teodoro J, Acurcio FA, Iunes RF, Guerra AA Jr. Gargano LP, et al. J Mark Access Health Policy. 2025 Dec 8;13(4):60. doi: 10.3390/jmahp13040060. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41450905 Free PMC article.

14

Cost-Effectiveness of Electrical Stimulation Therapy in the Treatment of Chronic Wounds: A Systematic Review, Meta-Analysis and Economic Analysis.

Smith JM, Posnett J, Woodmansey EJ. Smith JM, et al. J Mark Access Health Policy. 2025 Nov 24;13(4):59. doi: 10.3390/jmahp13040059. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41450904 Free PMC article. Review.

15

Patient Perspectives on Health Insurance Design: A Mixed-Methods Analysis.

Doherty B, Hooks K, Neumann U, Peters W, Zona S, Shea L. Doherty B, et al. J Mark Access Health Policy. 2025 Nov 14;13(4):56. doi: 10.3390/jmahp13040056. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41293064 Free PMC article.

16

The Impact of Copay Accumulators and Maximizers on Treatment Patterns, Adherence, and Costs Among Patients with Major Depressive and Bipolar Disorders Treated with Branded Therapies.

Baser O, Rodchenko K, Waters HC, Sullivan M, Wu L, Chen S, Shurtleff M, Bigley C, Patel R. Baser O, et al. J Mark Access Health Policy. 2025 Nov 7;13(4):55. doi: 10.3390/jmahp13040055. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41293063 Free PMC article.

17

Ezura M, Sawada K, Takushima Y, Teng L, Igarashi A. Ezura M, et al. J Mark Access Health Policy. 2025 Nov 14;13(4):57. doi: 10.3390/jmahp13040057. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41293062 Free PMC article.

18

Network Meta-Analysis of Bevacizumab Gamma Versus Competing Interventions for Treating Neovascular Age-Related Macular Degeneration in the United Kingdom.

Lorenzi M, Ebohon S, Kissner J, Comiskey J, Paap M, Bouchet C, Garnham A, Wissinger E. Lorenzi M, et al. J Mark Access Health Policy. 2025 Nov 19;13(4):58. doi: 10.3390/jmahp13040058. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41293061 Free PMC article. Review.

19

How the Stakeholders' Perception Contributes to the Pharmaceutical Strategies: A Regional Case Study in Latin America.

Ferreira TDS, Pauletti GM, Vázquez-Suárez L. Ferreira TDS, et al. J Mark Access Health Policy. 2025 Oct 23;13(4):54. doi: 10.3390/jmahp13040054. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41293060 Free PMC article.

20

Balancing Costs and Clinical Outcomes: A Cost-Effectiveness Study of PICC Types Across Chinese Healthcare Settings.

Xu J, Zare H, Yan X, Chiu HC, Castillo R. Xu J, et al. J Mark Access Health Policy. 2025 Sep 29;13(4):49. doi: 10.3390/jmahp13040049. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142930 Free PMC article.

21

Clinical and Economic Evidence Supporting the Value of Fluorescence Imaging of Bacteria in Wound Care.

Johnson J, Bohn G. Johnson J, et al. J Mark Access Health Policy. 2025 Sep 26;13(4):48. doi: 10.3390/jmahp13040048. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142929 Free PMC article. Review.

22

Examining State Policies and Administrative Factors as Determinants of Consumer-Reported Unmet Service Needs in Publicly Funded Home- and Community-Based Services in the United States.

Parikh RR, Shippee TP, Langworthy B, Wang Z, Giordano S, Jutkowitz E. Parikh RR, et al. J Mark Access Health Policy. 2025 Oct 2;13(4):51. doi: 10.3390/jmahp13040051. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142928 Free PMC article.

23

A Data-Driven Approach for Estimating Type 2 Diabetes-Related Costs in Greece.

Nika E, Tsiampalis T, Sachlas A, Liberopoulos E, Bersimis S, Georgakellos D. Nika E, et al. J Mark Access Health Policy. 2025 Oct 15;13(4):53. doi: 10.3390/jmahp13040053. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142927 Free PMC article.

24

Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward.

Standaert B, Topachevskyi O, Ethgen O. Standaert B, et al. J Mark Access Health Policy. 2025 Oct 2;13(4):50. doi: 10.3390/jmahp13040050. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142926 Free PMC article.

25

EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making.

Johns A, Andrade A, Johal S, Ryan J. Johns A, et al. J Mark Access Health Policy. 2025 Oct 9;13(4):52. doi: 10.3390/jmahp13040052. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142925 Free PMC article.

26

Shaping the Future of HTA in Italy: Insights from the Italian Health Policy Forum.

Sciattella P, Laurita R, Bini C, Di Brino E, Sacchini D, Nollo G. Sciattella P, et al. J Mark Access Health Policy. 2025 Sep 24;13(4):47. doi: 10.3390/jmahp13040047. eCollection 2025 Dec. J Mark Access Health Policy. 2025. PMID: 41142924 Free PMC article.

27

Shaping the Future of DHT Assessment: Insights on Industry Challenges, Developer Needs, and a Harmonized, European HTA Framework.

Mezei F, Tsiasiotis E, Basile M, Sciomenta I, Calosci EM, Antonini D, Lukacs A, Di Bidino R, Cicchetti A, Sacchini D. Mezei F, et al. J Mark Access Health Policy. 2025 Sep 4;13(3):46. doi: 10.3390/jmahp13030046. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40989745 Free PMC article.

28

Safe Staffing Standards for Pharmacy Technicians in Hospital Settings.

Silva V, Joaquim JJ, Desselle S, Quaye S, Matos C. Silva V, et al. J Mark Access Health Policy. 2025 Sep 4;13(3):45. doi: 10.3390/jmahp13030045. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40989742 Free PMC article.

29

Value-Based Healthcare as a Competitive Strategy-A Multi-Stakeholder Perception Analysis in Portuguese Healthcare.

Santiago F, Costa F, Redondo E, Matos C. Santiago F, et al. J Mark Access Health Policy. 2025 Sep 2;13(3):44. doi: 10.3390/jmahp13030044. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40989741 Free PMC article.

30

European Health Technology Assessment Considerations Related to Gene Therapies in Eyecare: The Neovascular Age-Related Macular Degeneration Example.

Douglas K, Pardhanani G, Mariani L, Chaita M. Douglas K, et al. J Mark Access Health Policy. 2025 Aug 27;13(3):42. doi: 10.3390/jmahp13030042. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40989744 Free PMC article.

31

Deploying Experienced Utility in Health Economic Evaluation: A Quantitative Study.

Broekharst DSE, Bloem S, Blomme RJ, Groenland EAG, Jeurissen PPT, van Agthoven M. Broekharst DSE, et al. J Mark Access Health Policy. 2025 Aug 28;13(3):43. doi: 10.3390/jmahp13030043. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40989743 Free PMC article.

32

Patient Involvement in Health Technology Assessments: Lessons for EU Joint Clinical Assessments.

Pickaert AP. Pickaert AP. J Mark Access Health Policy. 2025 Jul 28;13(3):38. doi: 10.3390/jmahp13030038. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860957 Free PMC article. Review.

33

Pivotal Studies for Drugs About to Be Launched for Rare Diseases: Will They Better Support Health Technology Assessment and Market Access than in the Past?

Jommi C, Bonfanti M, Guardigni M, Aiello A, Marcellusi A, Canonico PL, Luccini F, Lucchetti C. Jommi C, et al. J Mark Access Health Policy. 2025 Jul 25;13(3):37. doi: 10.3390/jmahp13030037. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860956 Free PMC article.

34

Managed Entry Agreements for Pharmaceutical Products in Three Maghreb Countries: Payer and Supplier Perspectives.

Dahmani H, Achour L; Maghreb Research Group; Toumi M, Fradi I. Dahmani H, et al. J Mark Access Health Policy. 2025 Aug 11;13(3):40. doi: 10.3390/jmahp13030040. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860955 Free PMC article.

35

Preparing for the EU HTA Regulation: Insights from the Dutch Perspective.

Willemsen A, Rutten-van Mölken M, Al Dulaimi R, Schelleman H, Goettsch W, Timmers L. Willemsen A, et al. J Mark Access Health Policy. 2025 Jul 24;13(3):35. doi: 10.3390/jmahp13030035. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860954 Free PMC article.

36

Physician Practice Affiliation Drives Site of Care Cost Differentials: An Opportunity to Reduce Healthcare Expenditures.

Kapoor DA, Camel M, Eagle D, Makhoul LC, Maroney J, Yang Z, Berggreen P. Kapoor DA, et al. J Mark Access Health Policy. 2025 Jul 24;13(3):36. doi: 10.3390/jmahp13030036. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860953 Free PMC article.

37

Development of a Work-Related Quality of Life Questionnaire for Medical Doctors (WQMD-9) in Japan: Questionnaire Design and Quantitative Survey.

Ezura M, Sawada K, Takushima Y, Teng L, Igarashi A. Ezura M, et al. J Mark Access Health Policy. 2025 Aug 19;13(3):41. doi: 10.3390/jmahp13030041. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860952 Free PMC article.

38

Innovative Payment Mechanisms for High-Cost Medical Devices in Latin America: Experience in Designing Outcome Protection Programs in the Region.

Paredes-Fernández D, Valencia-Zapata J. Paredes-Fernández D, et al. J Mark Access Health Policy. 2025 Aug 4;13(3):39. doi: 10.3390/jmahp13030039. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40860951 Free PMC article.

39

The PICO Puzzle: Can Public Data Predict EU HTA Expectations for All EU Countries?

Eberle K, Hagemann LM, Schweitzer MK, Justl M, Maurer J, Carls A, Reuter EM. Eberle K, et al. J Mark Access Health Policy. 2025 Jun 26;13(3):32. doi: 10.3390/jmahp13030032. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40709217 Free PMC article.

40

EU-HTA Guidance for Clinical Validity: Misconceptions and Flawed Processes.

Toumi M, Falissard B, Jouini A, Aballéa S, Boyer L, Auquier P. Toumi M, et al. J Mark Access Health Policy. 2025 Jul 15;13(3):33. doi: 10.3390/jmahp13030033. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40709216 Free PMC article. No abstract available.

41

An Estimation of the Economic and Environmental Impact of Inhaler Devices Switch for Non-Clinical Reasons in COPD and Asthma: The Case for Spain.

Solà-Morales O, Soriano JB, Solozabal-Coll M, Galindo JV. Solà-Morales O, et al. J Mark Access Health Policy. 2025 Jul 17;13(3):34. doi: 10.3390/jmahp13030034. eCollection 2025 Sep. J Mark Access Health Policy. 2025. PMID: 40709215 Free PMC article.

42

Opportunities for and Challenges of Conducting Indirect Treatment Comparisons and Meta-Analyses for Vaccines in Post-EU HTA Regulation Era.

Graham C, Barker E, Moss J, Gregg E, McCool R, Largeron N, Trichard M, Bartelt-Hofer J, Tribaldos M. Graham C, et al. J Mark Access Health Policy. 2025 Jun 11;13(2):31. doi: 10.3390/jmahp13020031. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568383 Free PMC article.

43

Exploring Trust in Health Insurers: Insights from Enrollees' Perceptions and Experiences.

van der Hulst FJP, Huijgen S, Brabers AEM, de Jong JD. van der Hulst FJP, et al. J Mark Access Health Policy. 2025 Jun 9;13(2):29. doi: 10.3390/jmahp13020029. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568384 Free PMC article.

44

Health Technology Assessment and Cardiology: A Review of the Present and Future of Innovation.

Casado-Arroyo R, Osoro L. Casado-Arroyo R, et al. J Mark Access Health Policy. 2025 Jun 9;13(2):30. doi: 10.3390/jmahp13020030. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568382 Free PMC article. Review.

45

Health and Social Care Integration: Insights from International Implementation Cases.

de Matos RC, do Nascimento G, Campos Fernandes A, Matos C. de Matos RC, et al. J Mark Access Health Policy. 2025 Jun 5;13(2):28. doi: 10.3390/jmahp13020028. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568385 Free PMC article.

46

Enhancing Patient Engagement in HTA: Using Consensus Research to Overcome PICO Scoping Challenges Under the EU HTAR.

Arcà E, Barlassina A, Eze A, Strammiello V. Arcà E, et al. J Mark Access Health Policy. 2025 Jun 2;13(2):27. doi: 10.3390/jmahp13020027. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568387 Free PMC article.

47

Price Analysis of Systemic Therapies and Transarterial Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma.

Williams AO, Anderson N, Gwon YG, Wifler W. Williams AO, et al. J Mark Access Health Policy. 2025 May 27;13(2):25. doi: 10.3390/jmahp13020025. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568386 Free PMC article.

48

The Art of Bridge Building: A Look at the European-Level Cooperation in HTA (EU-HTA).

Ivo RS, Rodrigues T, Couto S, Cossito M. Ivo RS, et al. J Mark Access Health Policy. 2025 May 28;13(2):26. doi: 10.3390/jmahp13020026. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568381 Free PMC article. No abstract available.

49

Optimizing Patient Access to Orphan Medicinal Products: Lessons from Central and Eastern Europe.

Kluszczynski T, Nemeth B, Władysiuk M, Czech M, Kamusheva M, Fotin N, Rose S, Doležal T, Hren R. Kluszczynski T, et al. J Mark Access Health Policy. 2025 May 26;13(2):24. doi: 10.3390/jmahp13020024. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40568380 Free PMC article.

50

Towards a Unified European View of Clinical Evidence: What 'Health Technology Assessment Organizations' Can Learn from Regulatory Experience.

Broich K, Löbker W. Broich K, et al. J Mark Access Health Policy. 2025 Apr 28;13(2):19. doi: 10.3390/jmahp13020019. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416337 Free PMC article.

51

Streamlining Endoscopy Cleaning: The Impact of a New Detergent on Time and Water Use.

Hicks J, Mutowo M. Hicks J, et al. J Mark Access Health Policy. 2025 May 16;13(2):23. doi: 10.3390/jmahp13020023. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416336 Free PMC article.

52

A New Health Networking Infrastructure on Cancer Is Taking Shape in Europe: A Not-to-Miss Opportunity for the EU Regulatory System.

Casali PG, Capri S. Casali PG, et al. J Mark Access Health Policy. 2025 Apr 28;13(2):18. doi: 10.3390/jmahp13020018. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416335 Free PMC article. No abstract available.

53

Effects of Primary Healthcare Quality and Effectiveness on Hospitalization Indicators in Brazil.

Freitas BL, Antiga MLOC, Sarti FM. Freitas BL, et al. J Mark Access Health Policy. 2025 May 9;13(2):21. doi: 10.3390/jmahp13020021. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416334 Free PMC article.

54

Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees.

Beck E, Joshi K, Mehta D, Lorenc S, Rizkalla B, Van de Velde N. Beck E, et al. J Mark Access Health Policy. 2025 Apr 24;13(2):17. doi: 10.3390/jmahp13020017. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416333 Free PMC article.

55

Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany.

Żerda I, Stanisz T, Fundament T, Chełmikowski F, Kłębczyk W, Pochopień M, Clay E, Aballéa S, Toumi M. Żerda I, et al. J Mark Access Health Policy. 2025 May 6;13(2):20. doi: 10.3390/jmahp13020020. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416332 Free PMC article.

56

Joint Scientific Consultation Eligibility Criterion: Hubris or Naïveté.

Toumi M, Falissard B, Boyer L, Auquier P. Toumi M, et al. J Mark Access Health Policy. 2025 May 15;13(2):22. doi: 10.3390/jmahp13020022. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40416331 Free PMC article. No abstract available.

57

Healthcare Professionals' Perceptions About Medical Cannabis in Greece: A Qualitative Study.

Ntais C, Melanthiou Y, Talias MA. Ntais C, et al. J Mark Access Health Policy. 2025 Apr 2;13(2):13. doi: 10.3390/jmahp13020013. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40276093 Free PMC article.

58

Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine Assessments.

Beekman J, de Roo A, Wolters S, Marapin R, Gurgel do Amaral G, Dvortsin E, Quilici S, de Waure C, Petelos E, Postma M, Viceré A. Beekman J, et al. J Mark Access Health Policy. 2025 Apr 18;13(2):16. doi: 10.3390/jmahp13020016. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40276092 Free PMC article.

59

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK.

Cooper N, Guterres S, Pochopień M, Wilson K, James S, Toumi M, Tytuła A, Rich C, Eriksson D. Cooper N, et al. J Mark Access Health Policy. 2025 Mar 24;13(2):11. doi: 10.3390/jmahp13020011. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40276091 Free PMC article.

60

ARM's Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path Ahead.

Morgese P, Majors S, Patel D. Morgese P, et al. J Mark Access Health Policy. 2025 Apr 3;13(2):14. doi: 10.3390/jmahp13020014. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40276090 Free PMC article.

61

A Methodological Proposal for Health Technology Assessments: A Case Study on Biosimilar Drugs.

Dimmito MP, Marinelli L, Toto EC, Di Biase G, Cacciatore I, Toto P, Ciulla M, Monti B, Santoleri F, Costantini A, Di Stefano A. Dimmito MP, et al. J Mark Access Health Policy. 2025 Mar 31;13(2):12. doi: 10.3390/jmahp13020012. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40276089 Free PMC article.

62

Clinical Trial Validity Guidance from the HTACG: Looking for Chicken Teeth.

Toumi M, Falissard B, Jouini A, Aballéa S, Boyer L. Toumi M, et al. J Mark Access Health Policy. 2025 Apr 16;13(2):15. doi: 10.3390/jmahp13020015. eCollection 2025 Jun. J Mark Access Health Policy. 2025. PMID: 40276088 Free PMC article. No abstract available.

63

Public Health Decision-Maker Perspective on Joint Clinical Assessments in Central European EU Member States.

Merész G, Dankó D, Molnár MP. Merész G, et al. J Mark Access Health Policy. 2025 Mar 4;13(1):10. doi: 10.3390/jmahp13010010. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 40144193 Free PMC article.

64

Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder Workshop.

Wang T, McAuslane N. Wang T, et al. J Mark Access Health Policy. 2025 Mar 3;13(1):9. doi: 10.3390/jmahp13010009. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 40144195 Free PMC article.

65

The Integration of Social and Health Sectors in Scotland: An Analysis from the Prism of Different Public Policy Models.

Correia de Matos R, do Nascimento G, Campos Fernandes A, Matos C. Correia de Matos R, et al. J Mark Access Health Policy. 2025 Feb 27;13(1):8. doi: 10.3390/jmahp13010008. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 40144194 Free PMC article.

66

Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy.

Julian E, Belleman T, Garcia MJ, Rutten-van Mölken M, Doeswijk R, Giuliani R, Wörmann BJ, Widmer D, Tilleul P, Casado Arroyo R, Strammiello V, Morgan K, Guardian M, Ermisch M, Bernardini R, Gianfrate F, Capri S, Uyl-de Groot CA, Pavlovic M, Ruof J. Julian E, et al. J Mark Access Health Policy. 2025 Feb 10;13(1):6. doi: 10.3390/jmahp13010006. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39990187 Free PMC article.

67

Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?

Armstrong H, Petrova A, Wilsdon T, Homoki H, Roediger A. Armstrong H, et al. J Mark Access Health Policy. 2025 Jan 24;13(1):2. doi: 10.3390/jmahp13010002. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39990186 Free PMC article.

68

Musculoskeletal Magazine Advertising Focuses on White Individuals and Overlooks Minority Consumers.

Tung WS, Rankin KA, Oris RJ, Wijesekera A, Wiznia DH. Tung WS, et al. J Mark Access Health Policy. 2025 Feb 4;13(1):4. doi: 10.3390/jmahp13010004. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39990185 Free PMC article.

69

Agenzia Italiana del Farmaco (AIFA): Developments and Strategy in a Transitioning European HTA Landscape.

Nisticò R. Nisticò R. J Mark Access Health Policy. 2025 Feb 5;13(1):5. doi: 10.3390/jmahp13010005. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39990184 Free PMC article. No abstract available.

70

Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID-19 Conditions: Findings from a Literature Review.

Łukomska E, Kloc K, Kowalska M, Matjaszek A, Joshi K, Scholz S, Van de Velde N, Beck E. Łukomska E, et al. J Mark Access Health Policy. 2025 Feb 12;13(1):7. doi: 10.3390/jmahp13010007. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39990183 Free PMC article. Review.

71

The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?

Tanner S, Coady R, Lisica A, Falla E, van Engen A. Tanner S, et al. J Mark Access Health Policy. 2025 Jan 30;13(1):3. doi: 10.3390/jmahp13010003. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39990182 Free PMC article.

72

Assessing the Value of Further Investment in R&D Using Mixed Methods: A Case Study of Biosensor-Integrated Arteriovenous Grafts.

Owusu Achiaw S, Hawkins N, Wu O, Mercer J. Owusu Achiaw S, et al. J Mark Access Health Policy. 2025 Jan 15;13(1):1. doi: 10.3390/jmahp13010001. eCollection 2025 Mar. J Mark Access Health Policy. 2025. PMID: 39867672 Free PMC article.

73

Managing Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies.

Ntais C, Talias MA, Fanourgiakis J, Kontodimopoulos N. Ntais C, et al. J Mark Access Health Policy. 2024 Dec 10;12(4):403-414. doi: 10.3390/jmahp12040031. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39735247 Free PMC article. Review.

74

Operational Efficiency of Public Hospitals in Greece During the COVID-19 Pandemic: A Comparative Analysis Using DEA and AHP Models.

Mitakos A, Mpogiatzidis P. Mitakos A, et al. J Mark Access Health Policy. 2024 Dec 10;12(4):388-402. doi: 10.3390/jmahp12040030. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39735246 Free PMC article.

75

Gatekeeping or Provider Choice for Sustainable Health Systems? A Literature Review on Their Impact on Efficiency, Access, and Quality of Services.

Ntais C, Kontodimopoulos N, Talias MA. Ntais C, et al. J Mark Access Health Policy. 2024 Dec 6;12(4):378-387. doi: 10.3390/jmahp12040029. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39735248 Free PMC article. Review.

76

Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach.

Sussman M, Benner J, Mugwagwa T, Lee J, Hung ST, Yang YM, Chen Y. Sussman M, et al. J Mark Access Health Policy. 2024 Nov 12;12(4):326-341. doi: 10.3390/jmahp12040026. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39588279 Free PMC article.

77

Economic Evidence on Cost Sharing and Alternative Insurance Designs to Address Moral and Behavioral Hazards in High-Income Health Care Systems: A Systematic Review.

Graf M, Baumgardner JR, Neumann U, Brewer IP, Chou JW, Fendrick AM. Graf M, et al. J Mark Access Health Policy. 2024 Nov 14;12(4):342-368. doi: 10.3390/jmahp12040027. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39588278 Free PMC article. Review.

78

Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines.

Okuyama R. Okuyama R. J Mark Access Health Policy. 2024 Oct 29;12(4):317-325. doi: 10.3390/jmahp12040025. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39588277 Free PMC article.

79

Technology Assessment vs. Technology Appraisal-How to Strengthen the Science/Value Dichotomy with EU HTA?

Gsteiger S, Bucher HC, Ryan J, Ruof J. Gsteiger S, et al. J Mark Access Health Policy. 2024 Nov 18;12(4):369-377. doi: 10.3390/jmahp12040028. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39588276 Free PMC article.

80

Adapting Efficiency Analysis in Health Systems: A Scoping Review of Data Envelopment Analysis Applications During the COVID-19 Pandemic.

Mitakos A, Mpogiatzidis P. Mitakos A, et al. J Mark Access Health Policy. 2024 Oct 22;12(4):306-316. doi: 10.3390/jmahp12040024. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39464180 Free PMC article.

81

INEAS's Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia.

Jameleddine M, Harzallah N, Grati H, Odabachian Jebali MC, Chemli J, García Martí S, Soto N, Pichon-Riviere A, Hamouda C. Jameleddine M, et al. J Mark Access Health Policy. 2024 Oct 6;12(4):294-305. doi: 10.3390/jmahp12040023. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39464179 Free PMC article.

82

A Causal Inference Approach to Mediation Analysis in Vitreomacular Traction: How Much Does Traction Resolution Mediate Functional Outcomes?

Lescrauwaet B, Vansteelandt S, Jackson TL, Sadda SR, Duchateau L. Lescrauwaet B, et al. J Mark Access Health Policy. 2024 Sep 30;12(4):280-293. doi: 10.3390/jmahp12040022. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39464178 Free PMC article.

83

The Knowledge and Application of Economics in Healthcare in a High-Income Country Today: The Case of Belgium.

Standaert B, Vandenberghe D, Connolly MP, Hellings J. Standaert B, et al. J Mark Access Health Policy. 2024 Sep 4;12(3):264-279. doi: 10.3390/jmahp12030021. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39315121 Free PMC article.

84

Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis.

Ingham M, Romdhani H, Patel A, Ashton V, Caron-Lapointe G, Tardif-Samson A, Lefebvre P, Lafeuille MH. Ingham M, et al. J Mark Access Health Policy. 2024 Sep 2;12(3):252-263. doi: 10.3390/jmahp12030020. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39315122 Free PMC article.

85

Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands.

Velikanova R, Wolters S, Hofstra HS, Postma MJ, Boersma C. Velikanova R, et al. J Mark Access Health Policy. 2024 Jul 30;12(3):181-198. doi: 10.3390/jmahp12030015. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193544 Free PMC article.

86

Valuation of Medical Innovation Handling with Uncertainty and Risk.

Nuijten M, Capri S. Nuijten M, et al. J Mark Access Health Policy. 2024 Aug 1;12(3):199-208. doi: 10.3390/jmahp12030016. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193543 Free PMC article.

87

Proposal of a Knowledge Management Model for Complex Systems: Case of the Supervision and Control Subsystem of the Colombian Health System.

Rodríguez-Páez FG, Cabrera-Moya D, Herrera-Cuartas JA. Rodríguez-Páez FG, et al. J Mark Access Health Policy. 2024 Aug 21;12(3):224-251. doi: 10.3390/jmahp12030019. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193542 Free PMC article.

88

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison.

Cherney D, Folkerts K, Mernagh P, Nikodem M, Pawlitschko J, Rossing P, Hawkins N. Cherney D, et al. J Mark Access Health Policy. 2024 Jul 25;12(3):169-180. doi: 10.3390/jmahp12030014. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193541 Free PMC article.

89

Adoption of a Societal Perspective in Economic Evaluations of Musculoskeletal Disorders: A Conceptual Paper.

Fatoye F, Gebrye T, Nherera L, Trueman P. Fatoye F, et al. J Mark Access Health Policy. 2024 Aug 12;12(3):216-223. doi: 10.3390/jmahp12030018. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193540 Free PMC article.

90

Patient Experience and Satisfaction with Orthopedic Services at a Community (Rural) Setting Hospital-How Is It Different from Urban Setting.

Hasan K, Kayum S. Hasan K, et al. J Mark Access Health Policy. 2024 Aug 5;12(3):209-215. doi: 10.3390/jmahp12030017. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193539 Free PMC article.

91

Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia.

Lagmay-Fuentes P, Smith A, Krus S, Lewis L, Latif A, Gagliardo T, Kohli M. Lagmay-Fuentes P, et al. J Mark Access Health Policy. 2024 Jul 10;12(3):158-168. doi: 10.3390/jmahp12030013. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39072307 Free PMC article.

92

The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy.

Julian E, Solà-Morales O, Garcia MJ, Brinkhuis F, Pavlovic M, Martín-Saborido C, Doeswijk R, Giuliani R, Willemsen A, Goettsch W, Wörmann B, Dafni U, Bucher HC, Pérez-Valderrama B, Bernardini R, Gianfrate F, Uyl-de Groot CA, Ruof J. Julian E, et al. J Mark Access Health Policy. 2024 Jun 22;12(3):128-143. doi: 10.3390/jmahp12030011. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39072306 Free PMC article.

93

Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.

Claessens Z, Lammens M, Barbier L, Huys I. Claessens Z, et al. J Mark Access Health Policy. 2024 Jul 9;12(3):144-157. doi: 10.3390/jmahp12030012. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39072305 Free PMC article.

94

Future Possible Changes in Medically Underserved Areas in Japan: A Geographic Information System-Based Simulation Study.

Nakamura A, Satoh E, Suzuki T, Koike S, Kotani K. Nakamura A, et al. J Mark Access Health Policy. 2024 Jun 3;12(2):118-127. doi: 10.3390/jmahp12020010. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38933412 Free PMC article.

95

Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance.

Thokagevistk K, Coppo C, Rey L, Carelli A, Díez V, Vaselenak S, Oliveira L, Patel A, Sicari E, Ramos T, Schach S, Schirghuber E, Simpson A, Choquet R, Le Lay K. Thokagevistk K, et al. J Mark Access Health Policy. 2024 May 20;12(2):105-117. doi: 10.3390/jmahp12020009. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38808313 Free PMC article.

96

Conceptualisation and Role of Market Access in Pharmaceutical Industry: A Scoping Review.

Fatoye C, Yeowell G, Miller E, Odeyemi I, Mbada C. Fatoye C, et al. J Mark Access Health Policy. 2024 May 1;12(2):81-99. doi: 10.3390/jmahp12020007. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38808312 Free PMC article.

97

EU HTA Regulation and Joint Clinical Assessment-Threat or Opportunity?

Schuster V. Schuster V. J Mark Access Health Policy. 2024 May 13;12(2):100-104. doi: 10.3390/jmahp12020008. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38808311 Free PMC article.

98

Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease.

Pochopien M, Dziedzic JW, Aballea S, Clay E, Zerda I, Toumi M, Borissov B. Pochopien M, et al. J Mark Access Health Policy. 2024 Apr 2;12(2):35-57. doi: 10.3390/jmahp12020005. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38660414 Free PMC article.

99

Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review.

Macabeo B, Quenéchdu A, Aballéa S, François C, Boyer L, Laramée P. Macabeo B, et al. J Mark Access Health Policy. 2024 Apr 16;12(2):58-80. doi: 10.3390/jmahp12020006. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38660413 Free PMC article. Review.

100

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.

Desmet T, Julian E, Van Dyck W, Huys I, Simoens S, Giuliani R, Toumi M, Dierks C, Dierks J, Cardone A, Houÿez F, Pavlovic M, Berntgen M, Mol P, Schiel A, Goettsch W, Gianfrate F, Capri S, Ryan J, Ducournau P, Solà-Morales O, Ruof J. Desmet T, et al. J Mark Access Health Policy. 2024 Mar 14;12(1):21-34. doi: 10.3390/jmahp12010004. eCollection 2024 Mar. J Mark Access Health Policy. 2024. PMID: 38544972 Free PMC article.

101

Comparative Clinical Effectiveness and Cost-Effectiveness of the Cochlear Osia System and Baha Attract System in Patients with Conductive or Mixed Hearing Loss or Single-Sided Deafness.

Brunner M, Schou M, Briggs RJ, Kingsford Smith D. Brunner M, et al. J Mark Access Health Policy. 2024 Mar 6;12(1):5-20. doi: 10.3390/jmahp12010003. eCollection 2024 Mar. J Mark Access Health Policy. 2024. PMID: 38544973 Free PMC article.

102

Welcome to the Journal of Market Access and Health Policy under MDPI Wings.

Toumi M. Toumi M. J Mark Access Health Policy. 2024 Jan 1;12(1):2-4. doi: 10.3390/jmahp12010002. eCollection 2024 Mar. J Mark Access Health Policy. 2024. PMID: 38445246 Free PMC article. No abstract available.

103

Publisher's Note: A New Chapter for the Journal of Market Access and Health Policy (JMAHP)-Continued Publication by MDPI.

Aunós C. Aunós C. J Mark Access Health Policy. 2024 Jan 1;12(1):1. doi: 10.3390/jmahp12010001. eCollection 2024 Mar. J Mark Access Health Policy. 2024. PMID: 38445245 Free PMC article. No abstract available.

104

Discounting health gain: a different view.

Standaert B, Ethgen O. Standaert B, et al. J Mark Access Health Policy. 2023 Nov 2;11(1):2275350. doi: 10.1080/20016689.2023.2275350. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37937314 Free PMC article.

105

Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey.

Fuat A, Ako E, Hargroves D, Holden D, Caleyachetty A, Carter M, Harris J, Roberts C, Nzeakor N, Vardar B, Williams H. Fuat A, et al. J Mark Access Health Policy. 2023 Oct 29;11(1):2267327. doi: 10.1080/20016689.2023.2267327. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37954532 Free PMC article.

106

Ivabradine in patients with heart failure: a systematic literature review.

Khan ZM, Briere JB, Olewinska E, Khrouf F, Nikodem M. Khan ZM, et al. J Mark Access Health Policy. 2023 Oct 4;11(1):2262073. doi: 10.1080/20016689.2023.2262073. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37808119 Free PMC article.

107

Patient perceptions of copay card utilization and policies.

Cavalier D, Doherty B, Geonnotti G, Patel A, Peters W, Zona S, Shea L. Cavalier D, et al. J Mark Access Health Policy. 2023 Sep 7;11(1):2254586. doi: 10.1080/20016689.2023.2254586. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37692554 Free PMC article.

108

Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.

Fens T, de Jong L, Kappelhoff B, Boersma C, Postma MJ. Fens T, et al. J Mark Access Health Policy. 2023 Sep 4;11(1):2247719. doi: 10.1080/20016689.2023.2247719. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37675057 Free PMC article.

109

Systematic literature reviews over the years.

Smela B, Toumi M, Świerk K, Gawlik K, Clay E, Boyer L. Smela B, et al. J Mark Access Health Policy. 2023 Aug 21;11(1):2244305. doi: 10.1080/20016689.2023.2244305. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37614556 Free PMC article.

110

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.

Dahmani H, Fradi I, Achour L, Toumi M; Maghreb Research Group. Dahmani H, et al. J Mark Access Health Policy. 2023 Aug 20;11(1):2244304. doi: 10.1080/20016689.2023.2244304. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37614557 Free PMC article. Review.

111

Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases.

Gibson E, Ollendorf DA, Simoens S, Bloom DE, Martinón-Torres F, Salisbury D, Severens JL, Toumi M, Molnar D, Meszaros K, Sohn WY, Begum N. Gibson E, et al. J Mark Access Health Policy. 2023 Aug 10;11(1):2239557. doi: 10.1080/20016689.2023.2239557. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37583879 Free PMC article.

112

Economic analysis of allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Center of Tunisia.

Achour L, Drira C, Sboui MZ, Fazaa I, Soussi MA, Hammami S, Ben Othman T, Razgallah Khrouf M. Achour L, et al. J Mark Access Health Policy. 2023 Aug 9;11(1):2236851. doi: 10.1080/20016689.2023.2236851. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37576087 Free PMC article.

113

Rapid literature review: definition and methodology.

Smela B, Toumi M, Świerk K, Francois C, Biernikiewicz M, Clay E, Boyer L. Smela B, et al. J Mark Access Health Policy. 2023 Jul 28;11(1):2241234. doi: 10.1080/20016689.2023.2241234. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37533549 Free PMC article. Review.

114

A systematic review of the characteristics of data assessment tools to measure medical doctors' work-related quality of life.

Ezura M, Sawada K, Takushima Y, Igarashi A, Teng L. Ezura M, et al. J Mark Access Health Policy. 2023 Jul 24;11(1):2234139. doi: 10.1080/20016689.2023.2234139. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37496728 Free PMC article. Review.

115

The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs.

Polek H, Janik J, Paterak E, Dabbous M, Pochopień M, Toumi M. Polek H, et al. J Mark Access Health Policy. 2023 Jul 10;11(1):2232648. doi: 10.1080/20016689.2023.2232648. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37440980 Free PMC article.

116

Reply to: comment on increased reliance on physician assistants: an access-quality tradeoff?.

Walia B, Banga H, Larsen D. Walia B, et al. J Mark Access Health Policy. 2023 Jul 5;11(1):2232192. doi: 10.1080/20016689.2023.2232192. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37426574 Free PMC article. No abstract available.

117

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments.

Aiello A, Mariano EE, Prada M, Teruzzi C, Martone N, Capri S, Carli G, Siragusa S. Aiello A, et al. J Mark Access Health Policy. 2023 Jun 30;11(1):2230663. doi: 10.1080/20016689.2023.2230663. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37405228 Free PMC article.

118

Transformative potential of artificial intelligence in global health policy.

Sifat RI, Bhattacharya U. Sifat RI, et al. J Mark Access Health Policy. 2023 Jun 30;11(1):2230660. doi: 10.1080/20016689.2023.2230660. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37405227 Free PMC article. No abstract available.

119

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.

Macabeo B, Wilson L, Xuan J, Guo R, Atanasov P, Zheng L, François C, Laramée P. Macabeo B, et al. J Mark Access Health Policy. 2023 Jun 13;11(1):2218633. doi: 10.1080/20016689.2023.2218633. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37325810 Free PMC article.

120

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire.

Van Haesendonck L, Ruof J, Desmet T, Van Dyck W, Simoens S, Huys I, Giuliani R, Toumi M, Dierks C, Dierks J, Cardone A, Houÿez F, Pavlovic M, Berntgen M, Mol PGM, Schiel A, Goettsch W, Gianfrate F, Capri S, Ryan J, Ducournau P, Solà-Morales O, Julian E. Van Haesendonck L, et al. J Mark Access Health Policy. 2023 Jun 4;11(1):2217543. doi: 10.1080/20016689.2023.2217543. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37284060 Free PMC article.

121

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States.

Klimchak AC, Sedita LE, Rodino-Klapac LR, Mendell JR, McDonald CM, Gooch KL, Malone DC. Klimchak AC, et al. J Mark Access Health Policy. 2023 May 26;11(1):2216518. doi: 10.1080/20016689.2023.2216518. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37261034 Free PMC article.

122

Quantitative revenue estimates and qualitative assessments of innovative fundraising sources for treating rare diseases in Colombia.

Walton SM, Mayorga W, Narváez AR, Chavez MA, Guesguán NC, Durango L, Parada LA. Walton SM, et al. J Mark Access Health Policy. 2023 May 11;11(1):2211868. doi: 10.1080/20016689.2023.2211868. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37187490 Free PMC article.

123

Artificial intelligence and remote patient monitoring in US healthcare market: a literature review.

Dubey A, Tiwari A. Dubey A, et al. J Mark Access Health Policy. 2023 May 3;11(1):2205618. doi: 10.1080/20016689.2023.2205618. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37151736 Free PMC article.

124

Implementation of equity and access in Indian healthcare: current scenario and way forward.

Ghia C, Rambhad G. Ghia C, et al. J Mark Access Health Policy. 2023 Mar 26;11(1):2194507. doi: 10.1080/20016689.2023.2194507. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36998432 Free PMC article. Review.

125

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy.

Aiello A, Mariano EE, Prada M, Cioni L, Teruzzi C, Manna R. Aiello A, et al. J Mark Access Health Policy. 2023 Feb 9;11(1):2176091. doi: 10.1080/20016689.2023.2176091. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36819891 Free PMC article.

126

Projecting direct medical costs and productivity benefits of improving access to advanced therapy for rheumatoid arthritis: a projection modelling study.

Foo CY, Mansor NAN, Ch'ng SS, Mohd Zain M. Foo CY, et al. J Mark Access Health Policy. 2023 Feb 8;11(1):2173117. doi: 10.1080/20016689.2023.2173117. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36819892 Free PMC article.

127

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.

Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L, Barry M. Carey N, et al. J Mark Access Health Policy. 2023 Jan 18;11(1):2166375. doi: 10.1080/20016689.2023.2166375. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36684853 Free PMC article.

128

The association between body mass index groups and metabolic comorbidities with healthcare and medication costs: a nationwide biobank and registry study in Finland.

Vesikansa A, Mehtälä J, Mutanen K, Lundqvist A, Laatikainen T, Ylisaukko-Oja T, Saukkonen T, Pietiläinen KH. Vesikansa A, et al. J Mark Access Health Policy. 2023 Jan 18;11(1):2166313. doi: 10.1080/20016689.2023.2166313. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36684852 Free PMC article.

129

Kato M, Yoneyama-Hirozane M, Iwasaki K, Matsubayashi M, Igarashi A. Kato M, et al. J Mark Access Health Policy. 2023 Jan 15;11(1):2166374. doi: 10.1080/20016689.2023.2166374. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36684854 Free PMC article.

130

Cost-effectiveness of infant hypoallergenic formulas to manage cow's milk protein allergy in France.

Paquete AT, Martins R, Connolly MP, Meulle M, Pastor N, Benoist G, Tounian P. Paquete AT, et al. J Mark Access Health Policy. 2022 Dec 10;11(1):2154418. doi: 10.1080/20016689.2022.2154418. eCollection 2023. J Mark Access Health Policy. 2022. PMID: 36518150 Free PMC article.

131

Innovative technologies for reverse total shoulder arthroplasty in Australia: Market access challenges and implications for patients, decision-makers, and manufacturers.

Gumbie M, Costa M, Erb M, Dissanayake G. Gumbie M, et al. J Mark Access Health Policy. 2022 Dec 6;11(1):2154420. doi: 10.1080/20016689.2022.2154420. eCollection 2023. J Mark Access Health Policy. 2022. PMID: 36506841 Free PMC article. Review.

132

Machine-learning prediction for hospital length of stay using a French medico-administrative database.

Jaotombo F, Pauly V, Fond G, Orleans V, Auquier P, Ghattas B, Boyer L. Jaotombo F, et al. J Mark Access Health Policy. 2022 Nov 26;11(1):2149318. doi: 10.1080/20016689.2022.2149318. eCollection 2023. J Mark Access Health Policy. 2022. PMID: 36457821 Free PMC article.

133

Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars.

Niazi SK, Al-Shaqha WM, Mirza Z. Niazi SK, et al. J Mark Access Health Policy. 2022 Nov 17;11(1):2147286. doi: 10.1080/20016689.2022.2147286. eCollection 2023. J Mark Access Health Policy. 2022. PMID: 36419638 Free PMC article.

134

Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis.

Margas W, Wojciechowski P, Toumi M. Margas W, et al. J Mark Access Health Policy. 2022 Aug 9;10(1):2106627. doi: 10.1080/20016689.2022.2106627. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35968522 Free PMC article.

135

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe.

Monleón C, Späth HM, Crespo C, Dussart C, Toumi M. Monleón C, et al. J Mark Access Health Policy. 2022 Jun 28;10(1):2094047. doi: 10.1080/20016689.2022.2094047. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35811835 Free PMC article. Review.

136

Public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease.

Millier A, Supiot R, Benyounes K, Machuron V, Le Lay K, Sivignon M, Leboucher C, Blein C, Raffi F. Millier A, et al. J Mark Access Health Policy. 2022 Jun 10;10(1):2082646. doi: 10.1080/20016689.2022.2082646. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35711615 Free PMC article.

137

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.

Fan L, Zhang Y, Maguire P, Muston D, Monberg M, Earla JR, Mihai A, Gulati P. Fan L, et al. J Mark Access Health Policy. 2022 Jun 8;10(1):2078474. doi: 10.1080/20016689.2022.2078474. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35693379 Free PMC article.

138

An integrated valuation model for payer and investor.

Nuijten M, Capri S. Nuijten M, et al. J Mark Access Health Policy. 2022 May 29;10(1):2080631. doi: 10.1080/20016689.2022.2080631. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35693380 Free PMC article.

139

Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario.

Duarte FA, Ferreira CG, Dienstmann R, Ferrari BL, Costa E Silva M, Nazareth A Junior P, Guilherme de O Salles P, Henrique C Diniz P. Duarte FA, et al. J Mark Access Health Policy. 2022 May 24;10(1):2077905. doi: 10.1080/20016689.2022.2077905. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 36353186 Free PMC article.

140

Can domestic medical tourism contribute to healthcare equity? A commentary.

Rydback M, Hyder A, Macassa G, Simonsson C. Rydback M, et al. J Mark Access Health Policy. 2022 Apr 5;10(1):2061241. doi: 10.1080/20016689.2022.2061241. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35399188 Free PMC article.

141

Cost-saving prediction model of transfer to palliative care for terminal cancer patients in a Japanese general hospital.

Hashimoto Y, Hayashi A, Tonegawa T, Teng L, Igarashi A. Hashimoto Y, et al. J Mark Access Health Policy. 2022 Mar 27;10(1):2057651. doi: 10.1080/20016689.2022.2057651. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35356234 Free PMC article.

142

Increased reliance on physician assistants: an access-quality tradeoff?

Walia B, Banga H, Larsen DA. Walia B, et al. J Mark Access Health Policy. 2022 Jan 24;10(1):2030559. doi: 10.1080/20016689.2022.2030559. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35087646 Free PMC article. No abstract available.

143

Psychometric validation of a patient-reported single-item assessment of 'Good Day Bad Day' in a neurogenic orthostatic hypotension population treated with droxidopa.

François C, Germain N, Majewska R, Taieb V, Hewitt LA, Kymes S. François C, et al. J Mark Access Health Policy. 2022 Jan 10;10(1):2010961. doi: 10.1080/20016689.2021.2010961. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35035792 Free PMC article.

144

Pricing Zolgensma - the world's most expensive drug.

Nuijten M. Nuijten M. J Mark Access Health Policy. 2021 Dec 29;10(1):2022353. doi: 10.1080/20016689.2021.2022353. eCollection 2022. J Mark Access Health Policy. 2021. PMID: 34992762 Free PMC article. No abstract available.

145

Burden of illness associated with pneumococcal infections in Japan - a targeted literature review.

Igarashi A, Ueyama M, Idehara K, Nomoto M. Igarashi A, et al. J Mark Access Health Policy. 2021 Dec 27;10(1):2010956. doi: 10.1080/20016689.2021.2010956. eCollection 2022. J Mark Access Health Policy. 2021. PMID: 34992761 Free PMC article. Review.

146

Does supplementary health insurance play a role in the switching behaviour of citizens in the Netherlands?

Holst L, Brabers A, de Jong J. Holst L, et al. J Mark Access Health Policy. 2021 Dec 15;10(1):2015863. doi: 10.1080/20016689.2021.2015863. eCollection 2022. J Mark Access Health Policy. 2021. PMID: 34925712 Free PMC article.

147

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models.

Pochopień M, Paterak E, Clay E, Janik J, Aballea S, Biernikiewicz M, Toumi M. Pochopień M, et al. J Mark Access Health Policy. 2021 Nov 13;9(1):2002006. doi: 10.1080/20016689.2021.2002006. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34790341 Free PMC article. Review.

148

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe.

Jabłońska K, Aballéa S, Auquier P, Toumi M. Jabłońska K, et al. J Mark Access Health Policy. 2021 Nov 11;9(1):2002008. doi: 10.1080/20016689.2021.2002008. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34790342 Free PMC article.

149

Manufacturers' views on outcome-based agreements.

Barjestehvan Waalwijk van Doorn-Khosrovani S, Timmers L, Pisters-van Roy A, Gijzen J, Blijlevens NMA, Bloemendal H. Barjestehvan Waalwijk van Doorn-Khosrovani S, et al. J Mark Access Health Policy. 2021 Oct 29;9(1):1993593. doi: 10.1080/20016689.2021.1993593. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34745459 Free PMC article.

150

Bright line or lottery? On significance and value in medical decision making.

Mahlich J, Dheban S. Mahlich J, et al. J Mark Access Health Policy. 2021 Sep 20;9(1):1981574. doi: 10.1080/20016689.2021.1981574. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34567476 Free PMC article.

151

The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population.

Hathway JM, Miller-Wilson LA, Sharma A, Jensen IS, Yao W, Raza S, Parks PD, Weinstein MC. Hathway JM, et al. J Mark Access Health Policy. 2021 Sep 1;9(1):1948670. doi: 10.1080/20016689.2021.1948670. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34512929 Free PMC article.

152

Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review.

Stavem K. Stavem K. J Mark Access Health Policy. 2021 Aug 20;9(1):1964792. doi: 10.1080/20016689.2021.1964792. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34434534 Free PMC article.

153

Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder.

Velez FF, Malone DC. Velez FF, et al. J Mark Access Health Policy. 2021 Aug 18;9(1):1966187. doi: 10.1080/20016689.2021.1966187. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34434535 Free PMC article.

154

Accelerating patient access to oncology medicines with multiple indications in Europe.

Lawlor R, Wilsdon T, Darquennes E, Hemelsoet D, Huismans J, Normand R, Roediger A. Lawlor R, et al. J Mark Access Health Policy. 2021 Aug 17;9(1):1964791. doi: 10.1080/20016689.2021.1964791. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34436506 Free PMC article. Review.

155

Informing decision makers seeking to improve vaccination programs: case-study Serbia.

Sauboin C, Mihajlović J, Postma MJ, Geets R, Antic D, Standaert B. Sauboin C, et al. J Mark Access Health Policy. 2021 Jul 25;9(1):1938894. doi: 10.1080/20016689.2021.1938894. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34367530 Free PMC article.

156

The effects of market concentration on health care price and quality in hospital markets in Ibadan, Nigeria.

Awoyemi BO, Olaniyan O. Awoyemi BO, et al. J Mark Access Health Policy. 2021 Jun 22;9(1):1938895. doi: 10.1080/20016689.2021.1938895. J Mark Access Health Policy. 2021. PMID: 34221255 Free PMC article.

157

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

Kansal AR, Reifsnider OS, Brand SB, Hawkins N, Coughlan A, Li S, Cragin L, Paramore C, Dietz AC, Caro JJ. Kansal AR, et al. J Mark Access Health Policy. 2021 Jun 7;9(1):1922028. doi: 10.1080/20016689.2021.1922028. J Mark Access Health Policy. 2021. PMID: 34178295 Free PMC article.

158

Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study.

Chandler C, Folse H, Gal P, Chavan A, Proskorovsky I, Franco-Villalobos C, Yang Y, Ward A. Chandler C, et al. J Mark Access Health Policy. 2021 Jun 3;9(1):1922163. doi: 10.1080/20016689.2021.1922163. J Mark Access Health Policy. 2021. PMID: 34122780 Free PMC article.

159

Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease.

Cook J, Bloom C, Lewis J, Marjenberg Z, Platz JH, Langham S. Cook J, et al. J Mark Access Health Policy. 2021 Jun 2;9(1):1929757. doi: 10.1080/20016689.2021.1929757. J Mark Access Health Policy. 2021. PMID: 34122781 Free PMC article.

160

Trends in US emergency department visits and subsequent hospital admission among patients with inflammatory bowel disease presenting with abdominal pain: a real-world study from a national emergency department sample database.

Ding Z, Patel A, Izanec J, Pericone CD, Lin JH, Baugh CW. Ding Z, et al. J Mark Access Health Policy. 2021 Apr 19;9(1):1912924. doi: 10.1080/20016689.2021.1912924. J Mark Access Health Policy. 2021. PMID: 33968334 Free PMC article.

161

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach.

Han R, Liang S, François C, Aballea S, Clay E, Toumi M. Han R, et al. J Mark Access Health Policy. 2021 Mar 25;9(1):1887664. doi: 10.1080/20016689.2021.1887664. J Mark Access Health Policy. 2021. PMID: 33828822 Free PMC article.

162

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).

Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Wiesner T, Malone DC, Bischof M, Toro W, Dabbous O. Dean R, et al. J Mark Access Health Policy. 2021 Feb 28;9(1):1889841. doi: 10.1080/20016689.2021.1889841. J Mark Access Health Policy. 2021. PMID: 33708361 Free PMC article.

163

A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in France.

Fernandes S, Fond G, Zendjidjian X, Michel P, Lançon C, Berna F, Schurhoff F, Aouizerate B, Henry C, Etain B, Samalin L, Leboyer M, Misdrahi D, Llorca PM, Coldefy M, Auquier P, Baumstarck K, Boyer L. Fernandes S, et al. J Mark Access Health Policy. 2021 Feb 23;9(1):1885789. doi: 10.1080/20016689.2021.1885789. J Mark Access Health Policy. 2021. PMID: 33680364 Free PMC article.

164

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany.

Wahler S, Müller A, Koll C, Seyed-Abbaszadeh P, Von Der Schulenburg JM. Wahler S, et al. J Mark Access Health Policy. 2020 Dec 28;9(1):1861804. doi: 10.1080/20016689.2020.1861804. J Mark Access Health Policy. 2020. PMID: 33456727 Free PMC article.

165

An algorithm to generate correlated input-parameters to be used in probabilistic sensitivity analyses.

Neine M, Curran D. Neine M, et al. J Mark Access Health Policy. 2020 Dec 15;9(1):1857052. doi: 10.1080/20016689.2020.1857052. J Mark Access Health Policy. 2020. PMID: 33403091 Free PMC article.

166

The impact of patent expiry on drug prices: insights from the Dutch market.

van der Schans S, Vondeling GT, Cao Q, van der Pol S, Visser S, Postma MJ, Rozenbaum MH. van der Schans S, et al. J Mark Access Health Policy. 2020 Dec 1;9(1):1849984. doi: 10.1080/20016689.2020.1849984. J Mark Access Health Policy. 2020. PMID: 33312457 Free PMC article.

167

Pricing of orphan drugs in oncology and rare diseases.

Nuijten M, Capri S. Nuijten M, et al. J Mark Access Health Policy. 2020 Dec 1;8(1):1838191. doi: 10.1080/20016689.2020.1838191. J Mark Access Health Policy. 2020. PMID: 33312455 Free PMC article.

168

Gene therapy randomised clinical trials in Europe - a review paper of methodology and design.

Ilieva K, Borissov B, Toumi M. Ilieva K, et al. J Mark Access Health Policy. 2020 Nov 23;8(1):1847808. doi: 10.1080/20016689.2020.1847808. J Mark Access Health Policy. 2020. PMID: 33312456 Free PMC article. Review.

169

Transitioning to community-based mental health service delivery: opportunities for Ukraine.

Quirke E, Suvalo O, Sukhovii O, Zöllner Y. Quirke E, et al. J Mark Access Health Policy. 2020 Nov 12;8(1):1843288. doi: 10.1080/20016689.2020.1843288. J Mark Access Health Policy. 2020. PMID: 33235691 Free PMC article.

170

Economic burden of spinal muscular atrophy: an analysis of claims data.

Belter L, Cruz R, Kulas S, McGinnis E, Dabbous O, Jarecki J. Belter L, et al. J Mark Access Health Policy. 2020 Nov 8;8(1):1843277. doi: 10.1080/20016689.2020.1843277. J Mark Access Health Policy. 2020. PMID: 33224449 Free PMC article.

171

Health economic evaluation of gene replacement therapies: methodological issues and recommendations.

Aballéa S, Thokagevistk K, Velikanova R, Simoens S, Annemans L, Antonanzas F, Auquier P, François C, Fricke FU, Malone D, Millier A, Persson U, Petrou S, Dabbous O, Postma M, Toumi M. Aballéa S, et al. J Mark Access Health Policy. 2020 Oct 11;8(1):1822666. doi: 10.1080/20016689.2020.1822666. J Mark Access Health Policy. 2020. PMID: 33144927 Free PMC article.

172

Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome.

Ezzedine K, Painchault C, Brignone M. Ezzedine K, et al. J Mark Access Health Policy. 2020 Oct 9;8(1):1829884. doi: 10.1080/20016689.2020.1829884. J Mark Access Health Policy. 2020. PMID: 33133432 Free PMC article.

173

Chinese guidelines related to novel coronavirus pneumonia.

Qiu T, Liang S, Dabbous M, Wang Y, Han R, Toumi M. Qiu T, et al. J Mark Access Health Policy. 2020 Oct 8;8(1):1818446. doi: 10.1080/20016689.2020.1818446. J Mark Access Health Policy. 2020. PMID: 33133431 Free PMC article. Review.

174

Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume medicare and medicaid physician providers.

Coleman C, Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B. Coleman C, et al. J Mark Access Health Policy. 2020 Oct 5;8(1):1829883. doi: 10.1080/20016689.2020.1829883. J Mark Access Health Policy. 2020. PMID: 33144928 Free PMC article.

175

A critical analysis and review of Lancet COVID-19 hydroxychloroquine study.

Toumi M, Biernikiewicz M, Liang S, Wang Y, Qiu T, Han R. Toumi M, et al. J Mark Access Health Policy. 2020 Sep 10;8(1):1809236. doi: 10.1080/20016689.2020.1809236. J Mark Access Health Policy. 2020. PMID: 33343837 Free PMC article. Review.

176

Organizational aspect in healthcare decision-making: a literature review.

Dubromel A, Duvinage-Vonesch MA, Geffroy L, Dussart C. Dubromel A, et al. J Mark Access Health Policy. 2020 Aug 31;8(1):1810905. doi: 10.1080/20016689.2020.1810905. J Mark Access Health Policy. 2020. PMID: 32944200 Free PMC article. Review.

177

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

Bowrin K, Briere JB, Levy P, Millier A, Tardu J, Toumi M. Bowrin K, et al. J Mark Access Health Policy. 2020 Jun 25;8(1):1782164. doi: 10.1080/20016689.2020.1782164. J Mark Access Health Policy. 2020. PMID: 32944199 Free PMC article.

178

Jarosławski S, Jarosławska B, Błaszczyk B, Auqier P, Toumi M. Jarosławski S, et al. J Mark Access Health Policy. 2020 Jun 17;8(1):1775933. doi: 10.1080/20016689.2020.1775933. J Mark Access Health Policy. 2020. PMID: 32944198 Free PMC article.

179

Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al.

Toumi M, Aballea S. Toumi M, et al. J Mark Access Health Policy. 2020 May 13;8(1):1758390. doi: 10.1080/20016689.2020.1758390. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32537099 Free PMC article.

180

Cost-consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer.

Jensen IS, Hathway J, Cyr P, Gauden D, Gardiner P. Jensen IS, et al. J Mark Access Health Policy. 2020 Apr 6;8(1):1749362. doi: 10.1080/20016689.2020.1749362. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32341772 Free PMC article.

181

Clinical efficacy assessment in severe vernal keratoconjunctivitis: preliminary validation of a new penalties-adjusted corneal fluorescein staining score.

Leonardi A, Dupuis-Deniaud M, Bremond-Gignac D. Leonardi A, et al. J Mark Access Health Policy. 2020 Apr 4;8(1):1748492. doi: 10.1080/20016689.2020.1748492. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32341771 Free PMC article.

182

Economic evaluation of biosimilars for reimbursement purposes - what, when, how?

Moorkens E, Broux H, Huys I, Vulto AG, Simoens S. Moorkens E, et al. J Mark Access Health Policy. 2020 Mar 15;8(1):1739509. doi: 10.1080/20016689.2020.1739509. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32284827 Free PMC article.

183

Specialist physician perspectives on non-medical switching of prescription medications.

Costa OS, Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, Coleman CI. Costa OS, et al. J Mark Access Health Policy. 2020 Mar 9;8(1):1738637. doi: 10.1080/20016689.2020.1738637. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32284826 Free PMC article.

184

Understanding the global measurement of willingness to pay in health.

McDougall JA, Furnback WE, Wang BCM, Mahlich J. McDougall JA, et al. J Mark Access Health Policy. 2020 Feb 15;8(1):1717030. doi: 10.1080/20016689.2020.1717030. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32158523 Free PMC article. Review.

185

Family caregiving in dementia and its impact on quality of life and economic burden in Japan-web based survey.

Igarashi A, Fukuda A, Teng L, Ma FF, Dorey J, Onishi Y. Igarashi A, et al. J Mark Access Health Policy. 2020 Feb 11;8(1):1720068. doi: 10.1080/20016689.2020.1720068. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32128076 Free PMC article.

186

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.

Standaert B, Sauboin C, DeAntonio R, Marijam A, Gomez J, Varghese L, Zhang S. Standaert B, et al. J Mark Access Health Policy. 2020 Jan 31;8(1):1719588. doi: 10.1080/20016689.2020.1719588. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32128075 Free PMC article. Review.

187

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.

Jørgensen J, Hanna E, Kefalas P. Jørgensen J, et al. J Mark Access Health Policy. 2020 Jan 15;8(1):1715536. doi: 10.1080/20016689.2020.1715536. eCollection 2020. J Mark Access Health Policy. 2020. PMID: 32082514 Free PMC article.

188

Tendering and biosimilars: what role for value-added services?

Simoens S, Cheung R. Simoens S, et al. J Mark Access Health Policy. 2019 Dec 22;8(1):1705120. doi: 10.1080/20016689.2019.1705120. eCollection 2020. J Mark Access Health Policy. 2019. PMID: 32002174 Free PMC article. Review.

189

Affordability of oncology drugs: accuracy of budget impact estimations.

Geenen JW, Jut M, Boersma C, Klungel OH, Hövels AM. Geenen JW, et al. J Mark Access Health Policy. 2019 Nov 30;8(1):1697558. doi: 10.1080/20016689.2019.1697558. eCollection 2020. J Mark Access Health Policy. 2019. PMID: 31839908 Free PMC article.

190

The impact of non-medical switching among ambulatory patients: an updated systematic literature review.

Weeda ER, Nguyen E, Martin S, Ingham M, Sobieraj DM, Bookhart BK, Coleman CI. Weeda ER, et al. J Mark Access Health Policy. 2019 Oct 19;7(1):1678563. doi: 10.1080/20016689.2019.1678563. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31692904 Free PMC article.

191

Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases.

Touya M, Lamy FX, Tanasescu A, Saragoussi D, François C, Wade AG, Llorca PM, Lançon C, Falissard B. Touya M, et al. J Mark Access Health Policy. 2019 Oct 9;7(1):1674115. doi: 10.1080/20016689.2019.1674115. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31656554 Free PMC article.

192

Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study.

Clay E, Zhou J, Yi ZM, Zhai S, Toumi M. Clay E, et al. J Mark Access Health Policy. 2019 Sep 26;7(1):1667195. doi: 10.1080/20016689.2019.1667195. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31595183 Free PMC article.

193

Medico-economic study of pain in an emergency department: a targeted literature review.

Dussart C, Gelas J, Geffroy L, de Fréminville H, Lvovschi VE. Dussart C, et al. J Mark Access Health Policy. 2019 Sep 13;7(1):1659099. doi: 10.1080/20016689.2019.1659099. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31552134 Free PMC article.

194

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results.

Zhou J, Millier A, François C, Aballéa S, Toumi M. Zhou J, et al. J Mark Access Health Policy. 2019 Aug 22;7(1):1648973. doi: 10.1080/20016689.2019.1648973. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31489150 Free PMC article. Review.

195

Why "American Patients First" is likely to raise drug prices outside of the United States.

Dabbous M, Milea C, Simoens S, François C, Dussart C, Chachoua L, Borissov B, Toumi M. Dabbous M, et al. J Mark Access Health Policy. 2019 Aug 9;7(1):1650596. doi: 10.1080/20016689.2019.1650596. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31489151 Free PMC article. Review.

196

Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma.

Armoiry X, Spath HM, Clarke A, Connock M, Sutcliffe P, Dussart C. Armoiry X, et al. J Mark Access Health Policy. 2019 Jul 30;7(1):1648971. doi: 10.1080/20016689.2019.1648971. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31489149 Free PMC article. Review.

197

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate.

Jørgensen J, Kefalas P. Jørgensen J, et al. J Mark Access Health Policy. 2019 Jun 27;7(1):1635842. doi: 10.1080/20016689.2019.1635842. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31303982 Free PMC article.

198

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.

Clay E, Cristeau O, Chafaie R, Pinta A, Mazaleyrat B, Cottin V. Clay E, et al. J Mark Access Health Policy. 2019 Jun 24;7(1):1626171. doi: 10.1080/20016689.2019.1626171. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31275535 Free PMC article.

199

Correction.

[No authors listed] [No authors listed] J Mark Access Health Policy. 2019 Jun 11;7(1):1626572. doi: 10.1080/20016689.2019.1626572. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31231483 Free PMC article.

200

Measuring the health-related quality of life in young children: how far have we come?

Germain N, Aballéa S, Toumi M. Germain N, et al. J Mark Access Health Policy. 2019 May 22;7(1):1618661. doi: 10.1080/20016689.2019.1618661. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 31156762 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

327 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Results by year